NCE-1 Intelligence & Market Opportunity

Brexafemme

Ibrexafungerp

Antifungal

Oral Tablet

Approval Date

06-Jan-21

NCE-1 Date

06-Jan-25

NCE Date

06-Jan-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

2.673

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

127

2029

182

2030

235

2031

288

2032

343

Molecule profile

Details & specifications

Molecule

Ibrexafungerp

Innovator

GLAXOSMITHKLINE

Dosage Form

Oral Tablet

Strength

EQ 150 mg base

Therapeutic Category

Antifungal

Usage

To treat vulvovaginal candidiasis

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.